EUVIMEDEUVIMED entdecken
Open Access

Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival

Borja Puertas, Irene Padilla, Elena Alejo, Fe Serra-Toral, Aránzazu García-Mateo, Rosa López-López, Abelardo Bárez, José María Alonso-Alonso, Carlos Aguilar-Franco, Erik de Cabo, Alberto Cantalapiedra-Diez, Alfonso García-Coca und 13 weitere

British Journal of Haematology · 2026-08 · 209 (2) · 569-579

DOI: 10.1111/bjh.70606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 18.06.2026. Verfasst von Borja Puertas und 24 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Inv…. Hauptthemen laut MEDLINE: Multiple Myeloma, Neoplasm, Residual, Blood Component Removal. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While measurable residual disease (MRD) in bone marrow (bmMRD) is a validated surrogate biomarker in multiple myeloma (MM), the clinical relevance of MRD in the apheresis product (aMRD) remains unclear. We retrospectively analysed 422 MM patients who underwent autologous stem cell transplantation (ASCT) between 2005 and 2023 at the University Hospital of Salamanca, all evaluated for aMRD by 8‐colour flow cytometry. Overall, 45 patients (10%) were aMRD+ve and 377 (90%) were aMRD−ve, with similar baseline characteristics except for a higher frequency of t(11;14) in aMRD+ve cases. Patients with responses worse than a very good partial response before apheresis were six times more likely to be aMRD+ve (odds ratio [OR] 6.6, p = 0.006), and notably, no patients with bmMRD−ve status prior to apheresis were aMRD+ve. After ASCT, patients with aMRD+ve exhibited lower rates of complete response and bmMRD−ve than patients with aMRD−ve, leading to a shorter progression‐free survival (hazard ratio 1.7, p = 0.006), and aMRD+ve status was identified as an independent predictor of early relapse (OR 9.75, p = 0.007). These findings may suggest that aMRD+ve serves as a critical early biomarker to identify suboptimal treatment responses, reflecting bmMRD persistence and predicting inferior clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaNeoplasm, ResidualBlood Component RemovalHumansFemaleRetrospective StudiesMaleMiddle AgedAgedAdultTransplantation, AutologousHematopoietic Stem Cell Transplantation

Stichwörter der Autor:innen

ASCTMRDearly relapse

Autor:innen und Institutionen

  • Hematology Department, University Hospital of Salamanca/Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
  • Hematology Department, University Hospital of León, IBILEON, León, Spain.
  • Hematology Department, University Hospital of Burgos, Burgos, Spain.
  • Hematology Department, University Hospital of Segovia, Segovia, Spain.
  • Hematology Department, University Hospital of Virgen del Puerto, Plasencia, Spain.
  • Hematology Department, University Hospital Nuestra Señora de Sonsoles, Ávila, Spain.

ORCID-Profile: María-Victoria Mateos

Zitieren

APA

Puertas, B., Padilla, I., Alejo, E., Serra-Toral, F., García-Mateo, A., López-López, R., Bárez, A., Alonso-Alonso, J. M., Aguilar-Franco, C., de Cabo, E., Cantalapiedra-Diez, A., García-Coca, A., Hernández, R., Rey-Búa, B., Fonseca-Santos, M., López-Parra, M., López-Corral, L., Gutiérrez, N. C., Vidriales-Vicente, M. B., …, & Puig, N. (2026). Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival. British Journal of Haematology, 209(2), 569-579. https://doi.org/10.1111/bjh.70606

Vancouver

Puertas B, Padilla I, Alejo E, Serra-Toral F, García-Mateo A, López-López R, et al. Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival. British Journal of Haematology. 2026;209(2):569-579. doi:10.1111/bjh.70606

BibTeX
@article{Puertas2026,
  author = {Puertas, Borja and Padilla, Irene and Alejo, Elena and Serra-Toral, Fe and García-Mateo, Aránzazu and López-López, Rosa and Bárez, Abelardo and Alonso-Alonso, José María and Aguilar-Franco, Carlos and de Cabo, Erik and Cantalapiedra-Diez, Alberto and García-Coca, Alfonso and Hernández, Roberto and Rey-Búa, Beatriz and Fonseca-Santos, Marta and López-Parra, Miriam and López-Corral, Lucía and Gutiérrez, Norma C and Vidriales-Vicente, María Belén and Pérez, José J and González-Calle, Verónica and Mateos, María-Victoria and Escalante, Fernando and Flores-Montero, Juan and Puig, Noemi},
  title = {Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {209},
  number = {2},
  pages = {569--579},
  doi = {10.1111/bjh.70606}
}
Kostenlos starten →